Mokina, T V, Antipenko, E A, Gustov, A V · Neuroscience and behavioral physiology · 2010 · DOI
This study looked at whether a medication called adaptol could help people with ME/CFS who also had reduced blood flow to the brain. Researchers observed patients taking adaptol and tracked whether it helped with their fatigue and other symptoms. This was an early-stage observation study designed to see if adaptol might be worth studying more carefully in the future.
This study explores whether adaptol—a medication with anxiolytic and neuroprotective properties—may have therapeutic potential for ME/CFS, particularly in patients with vascular complications. Understanding treatments tailored to ME/CFS patients with comorbid cerebral ischemia could inform management strategies for this complex patient subset.
This observational study does not establish that adaptol is effective for ME/CFS, as it lacks a control group, blinding, or randomization. The findings cannot distinguish between adaptol's effects, natural disease variation, placebo response, or other concurrent treatments. No causal relationship between adaptol and symptom improvement can be concluded from this study design.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →